[Contraindications of thrombolytic therapy in acute myocardial infarct].
In 43 Swiss hospitals, 824 patients have been included in the ISIS-3 trial with suspected or proven myocardial infarction. Another 504 patients with proven myocardial infarction have been excluded for various reasons and have been registered in the study log-book (total 1328 patients). The usual clinical contraindications for thrombolysis are listed and discussed in this paper. 1/3 of those patients excluded from the trial had not received thrombolysis without clear contraindications (age, diabetes, anticoagulation, candidates for a pace-maker) and another 27% have had only relative contraindications (resuscitation, puncture, ulcer pain, hypertension). The new guidelines for thrombolytic therapy allowed more patients to benefit from this therapy.
Genoni
M
M
Clinica Medica Ospedale Civico, Lugano, Schweiz.
Malacrida
R
R
Maggioni
A
A
Moccetti
T
T
D000328:Adult; D000368:Aged; D000075202:Contraindications; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D018579:Patient Selection; D011446:Prospective Studies; D012307:Risk Factors; D013557:Switzerland; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents
Kontraindikationen der thrombolytischen Therapie beim akuten Myokardinfarkt.